Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring (Q30412650)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

0 references

Emanual Maverakis

object named as

Emanual Maverakis

7

0 references

Raja K Sivamani

1

object named as

Raja K Sivamani

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

author name string

Heidi Goodarzi

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Miki Shirakawa Garcia

3

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Siba P Raychaudhuri

4

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Lisa N Wehrli

5

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Yoko Ono

6

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Clinical Reviews in Allergy & Immunology

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

121-140

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Psoriasis--epidemiology and clinical spectrum

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Prevalence of joint disease in patients with psoriasis: implications for therapy

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Human fibroblasts support the expansion of IL-17-producing T cells via up-regulation of IL-23 production by dendritic cells

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Differences in binding and effector functions between classes of TNF antagonists

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

A lymphotoxin-beta-specific receptor

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Network communications: lymphotoxins, LIGHT, and TNF.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Immunogenicity of engineered antibodies

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

A randomized trial of etanercept as monotherapy for psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatment of acrodermatitis continua of Hallopeau with TNF-blocking agents: case report and review

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade)

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

How early should psoriatic arthritis be treated with a TNF-blocker?

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event–free response days in the CHAMPION trial

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Onset of multiple sclerosis associated with anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Autoimmune Diseases Induced by TNF-Targeted Therapies

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune re

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Self-reactive T cells and degeneracy of T cell recognition: evolving concepts-from sequence homology to shape mimicry and TCR flexibility.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The etiology of paraneoplastic autoimmunity

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Light, including ultraviolet

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatments for psoriasis and the risk of malignancy

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tuberculosis in the age of biologic therapy

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Biologics and infections: lessons from tumor necrosis factor blocking agents

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Anti-tumor necrosis factor therapy and interpreting tuberculin skin tests

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Interferon- release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Predictors of discordant tuberculin skin test and QuantiFERON®-TB Gold In-Tube results in various high-risk groups

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Tuberculosis associated with therapy against tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic?

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Treatment of palmoplantar psoriasis with intramuscular alefacept.

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Biological therapy of psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin

1 reference

https://api.crossref.org/works/10.1007/S12016-012-8301-7

21 January 2018

Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of etanercept in psoriatic patients previously treated with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful use of adalimumab (Humira) for Crohn's disease in pregnancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cells involved in psoriasis vulgaris belong to the Th1 subset

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab in recalcitrant generalized pustular arthropatic psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriasiform Drug Eruption due to Abatacept

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open label trial of alefacept in palmoplantar pustular psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutrophil chemotaxis in psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tuberculosis and treatment with infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept-induced psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intestinal function and methotrexate absorption in psoriatic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of tumor necrosis factor antagonists.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the treatment of palmoplantar pustulosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of erythrodermic psoriasis with etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22311162

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12016-012-8301-7

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30412650&oldid=2194831465"